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1. Introduction 
Coronary artery disease (CAD) is a narrowing or blockage of the arteries and vessels that 
provide oxygen and nutrients to the heart. It is caused by atherosclerosis, an accumulation 
of fatty materials on the inner linings of arteries. According to the American Heart 
Association and American Stroke Association's 2010 publication on heart disease and stroke 
statistics, cardiovascular disease remains the leading cause of mortality in the United States 
in men and women of every major ethnic group. It accounts for nearly 1 million deaths per 
year as of 2006 and was responsible for one in almost three deaths in the United States in 
2006. Approximately 17 million persons have a history of coronary artery disease and 8 
million have suffered a myocardial infarction (American Heart Association 2010). 
Medication and invasive revascularization are the most common approaches for treating 
CAD. Invasive revascularization includes percutaneus coronary interventions (PCI: stent 
implantation or balloon angioplasty)and Coronary Bypass Surgery (CABG). Even though 
both treatment options are commonly used, it is important to note that neither of these 
approaches provides a cure. In other words, although the symptoms are eliminated or 
alleviated, the disease and its causes are still present after treatment. Both treatments target 
lesions that cause the obstructions however, CAD is a progressive disease. New treatment 
approaches are in need to prevent the disease from progressing and the symptoms from 
recurring. Enhanced External Counterpulsation (EECP) therapy with its different mode of 
action provides a new treatment modality in the management of CAD and complements the 
invasive revascularization (Fig. 1).  
This chapter summarizes the current evidence to support the role of EECP therapy in CAD 
management and provides information on its mechanism of action. 
2. What is EECP? 
EECP therapy consists of a treatment bed attached to an air compressor unit which is 
attached to a computerized control console. Three sets of cuffs wrapped around the lower 
legs and the buttocks of the patient. It is a noninvasive outpatient therapy consisting of 
electrocardiography (ECG)-gated sequential leg compression, which produces 
hemodynamic effects similar to those of an intra-aortic balloon pump (IABP) (Fig. 2).  
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EECP Therapy: Consisting of a patient bed attached to an air compressor unit; computerized control 
consul; 3 sets of cuffs wrapped around the lower legs and the buttocks of the patient. (With permission 
from Vasomedical Inc., NY). EECP: Enhanced External Counterpulsation 
Fig. 1. EECP Therapy 
 
 
Three pairs of pneumatic cuffs are applied to the calves, lower thighs, and upper thighs. The cuffs are 
inflated sequentially during diastole, distal to proximal. The compression of the lower extremity 
vascular bed increases diastolic pressure and flow and increases venous return. The pressure is then 
released at the onset of systole. Inflation and deflation are timed according to the R wave on the 
patient’s cardiac monitor. The pressures applied and the inflation–deflation timing can be altered by 
using the pressure waveforms and ECG on the EECP therapy monitor. (Adapted from Manchanda and 
Soran 2007) 
ECG: Electrocardiogram; EECP: Enhanced External Counterpulsation   
Fig. 2. Technique of EECP Therapy 
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However, unlike IABP therapy, EECP therapy also increases venous return (Manchanda 
and Soran 2007, Birtwell et al 1968). Cuffs resembling oversized blood pressure cuffs—on 
the calves and lower and upper thighs, including the buttocks—inflate rapidly and 
sequentially via computer interpreted ECG signals, starting from the calves and proceeding 
upward to the buttocks during the resting phase of each heartbeat (diastole). This creates a 
strong retrograde counterpulse in the arterial system, forcing freshly oxygenated blood 
toward the heart and coronary arteries while increasing the volume of venous blood return 
to the heart under increased pressure. Just before the next heartbeat, before systole, all three 
cuffs deflate simultaneously, significantly reducing the heart’s workload. This is achieved 
because the vascular beds in the lower extremities are relatively empty when the cuffs are 
deflated; significantly lowering the resistance to blood ejected by the heart and reducing the 
amount of work the heart must do to pump oxygenated blood to the rest of the body. A 
finger plethysmogram is used throughout treatment to monitor diastolic and systolic 
pressure waveforms. The current EECP device can generate external cuff pressures as high 
as 220 to 300 mmHg. A typical therapy course consists of 35 treatments administered for 1 
hour a day over 7 weeks.  
2.1 Historical perspective 
The concept of counterpulsation was introduced in the U.S. in 1953 when Kantrowitz first 
proposed that elevations of aortic diastolic pressure could improve coronary blood flow and 
could benefit patients with coronary insufficiency. Although subsequent studies suggested 
that counterpulsation would indeed benefit some patients with coronary insufficiency, the 
development of the necessary technology proved challenging. A group of devices that 
increased coronary blood flow, including flow assist devices and venoarterial bypass 
systems, proved effective in providing increased coronary blood flow but were unable to 
reduce the tension time index or work load of the heart. External cardiac massage, internal 
cardiac massage, veno-arterial bypass, implantable auxillary ventricules, intra-aortic balloon 
pumps, and cardiopulmonary bypass have all demonstrated hemodynamic benefits; 
however, their usefulness in clinical practice has been limited because of their inherent 
invasiveness. 
In the mid 1960s, several groups began to explore a non-invasive method for producing the 
salutary physiologic effects of counterpulsation. First external countrepulation device 
introduced by Harvard investigators, consisted of a hydraulically driven unit with a pair of 
water –filled bladders that could be wrapped around the lower legs and thighs of the 
patient. (Birtwell et al, 1968) However, the external pressure could only be applied to a 
limited amount of tissue mass thereby producing suboptimal diastolic augmentation of 
coronary flow. Investigators did not give up on the idea and kept working on to improve 
the technology. Over the years air-driven EECP system consisting of three sets of balloons 
wrapped around the lower legs, thighs and upper thighs of the patient has been developed. 
Air pressure was applied sequentially from the lower legs to the thigh and upper thigh 
resulting in “milking” of oxygenated blood from the lower extremities toward the heart 
with greater efficiency. (Amsterdam et al.,1980; Zeng et al., 1983). It has been demonstrated 
that the sequential inclusion of the upper thigh provided a critical advantage to EECP, 
affecting a 44% increase in diastolic augmentation compared with studies using only the 
lower extremity cuffs. Subsequent modifications of the EECP prototype with 
microprocessors allowed for precise cuff inflation and deflation and gating with the 
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electrocardiogram. The lower cuffs were inflated at the start of diastole as represented by 
the beginning of the T wave, while simultaneous deflation of all three chambers was 
triggered just prior to systole at the onset of the P wave. The retrograde flow provided by 
EECP increased both the volume and pressure of diastolic flow such that diastolic to systolic 
ratios exceeded 1.0-1.2. (Soran et al., 1999). In summary, it took 40 years for investigators to 
develop the enhanced technology that is being currently used. (Fig 1) 
2.2 Acute hemodynamic effects of EECP therapy 
Acute hemodynamic effects of EECP has been assessed through both noninvasive and 
invasive techniques.(Soran  et al., 2001;  Stys et al., 2001; Michaelset al.,2001; Lakshmi et al. 
2002; Nichols et al., 2006; Taguchi  et al., 2004). 
Taguchi et al, assessed the hemodynamic effects of EECP and compared it with IABP in 39 
patients with uncomplicated acute myocardial infarction who underwent successful balloon 
coronary angioplasty within 12 hours after onset of chest pain. The radial artery and 
subclavian vein were cannulated to measure right atrial pressure, pulmonary capillary 
wedge pressure (PCWP), cardiac index, and systemic vascular resistance. Radial artery 
pressure tracing was used to measure area under artery pressure curves in systolic and 
diastolic phases. Sixty minutes treatment was administered to the patients in the EECP 
group. All parameters were measured before EECP, at 15, 30, 45, and 60 minutes after 
starting EECP, and 60 minutes after stopping EECP. After starting IABP support, 
measurements were obtained at 15, 30, 45, and 60 minutes. There were no significant 
changes in heart rate in either group before, during, and after treatments. Right atrial 
pressure increased significantly at 15 and 30 minutes after starting EECP, and then 
decreased gradually. There was no significant increase in right atrial pressure at 45 and 60 
minutes after starting EECP compared with baseline. Right atrial pressure did not change in 
the IABP group, and there was no significant difference between 2 groups, except at 15 
minutes after starting treatment. In the EECP group the PCWP significantly increased at 15 
and 30 minutes, and then decreased gradually, but no significant change was seen in IABP 
group. Between two groups, there were no significant differences at baseline and during 
treatment. However, 60 minutes after stopping treatment, PCWP was significantly lower in 
the EECP group. The cardiac index in EECP group increased significantly at 45 and 60 
minutes compared with the baseline, but no significant change was noted in IABP group. 
The increase in cardiac index at 60 minutes in the EECP group was significantly greater than 
that in the IABP group. Mean values of the area under the arterial pressure curves during 
the diastolic phase increased significantly in both groups, and there was no significant 
difference between two groups at any measuring point. Mean values of the areas under the 
artery pressure curves during the systolic phase decreased significantly during treatment 
compared with baseline in the IABP group. No significant change was observed in the EECP 
group. In both groups, systemic vascular resistance decreased significantly during treatment 
compared with baseline, but no significant difference was seen between two groups. This 
study showed that the hemodynamic effects of EECP were similar to those of IABP for 
diastolic augmentation and systemic vascular resistance. However, right atrial pressure, 
PCWP, and cardiac index increased during EECP in contrast to IABP. These effects suggest 
that EECP increases venous return, raises cardiac preload, and increases cardiac output. 
(Taguchi et al., 2004; Michaels et al., 2009) 
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In another study, Taguchi et al., assessed the hemodynamic and neurohormonal changes 
during EECP. Sixty minutes of EECP therapy has been performed in  patients with stable 
acute myocardial infarction who had undergone PCI. Right heart catheterization and 
neurohumoral parameters were assessed before, during 15, 30 and 60 minutes after EECP. 
Blood levels of atrial natriuretic peptide (ANP), brain (or B type) natriuretic peptide (BNP), 
renin, aldosterone, dopamine, and noradrenaline were assessed. Left ventricular ejection 
fraction and size were assessed invasively during the admission and between days 13 to 16. 
Cardiac index increased from 3.3±0.8 L/min before treatment to 4.1±0.8 L/min at 60 
minutes (P<0.01). Right atrial pressure increased from 6.4±3.3 mmHg at baseline to 9.8±4.0 
mmHg at 15 minutes (P<0.01), and PCWP increased from 8.9±4.0 mmHg to 12.6±5.3 mmHg 
(P<0.05). The blood levels of ANP increased from 54±42 pg/ml at baseline to 70±46 pg/ml at 
60 minutes, which returned to baseline level 60 minutes after EECP treatment. The 
pretreatment concentrations of BNP, dopamine, noradrenaline, renin and aldosterone did 
not change during or after EECP treatment. Left ventricular end-diastolic pressure 
decreased from 18.6±1.6 mmHg during the acute stage to 13.8±6.4 mmHg during subacute 
follow-up, but there was no change in left ventricular ejection fraction or end-diastolic 
volume index. Blood concentrations of ANP increased at 15 minutes after initiation of EECP, 
which suggested that EECP treatment increased the volume of venous return, resulting in 
an increased atrial load. EECP significantly improved cardiac index with a significant 
increase in blood ANP concentration but without increase in heart rate or BNP. These 
findings suggest that there be an increased atrial preload without any significant change in 
ventricular preload.( Taguchi et al.,2004; Michaels et al., 2010) 
Michaels et al., used an invasive approach to measure intracoronary, central aortic, and left 
ventricular pressure and intracoronary Doppler flow to assess the acute hemodynamic 
effects of EECP. Ten patients who were referred for cardiac catheterization (5 with suspected 
coronary artery disease, 3 with severe mitral regurgitation, and 2 with heart transplant 
patients) were included in the study. Key exclusion criteria included severe aortic 
insufficiency, decompensated heart failure, significant arrhythmia, systolic blood pressure 
more than 180 mmHg, and symptomatic peripheral arterial disease. EECP was performed at 
external cuff pressures ranging from 100 to 300 mmHg. At baseline and during EECP, 
simultaneous central aortic and intracoronary pressure, intracoronary Doppler flow 
velocity, and corrected thrombosis in Myocardial Infarction study (TIMI) frame count 
(CTFC) were measured. Peak aortic systolic pressure decreased 11% from 114 ±19 mmHg at 
baseline to 101±28 mmHg during EECP (P=0.02). These findings indicate that EECP acutely 
reduces ventricular afterload. Left ventricular end-diastolic pressure decreased during EECP 
(15±7 mmHg at baseline, 13±6 mmHg during EECP; P=0.17). Aortic diastolic pressure 
increased 92% from 71±10 mmHg to 136±22 mmHg (P<0.0001), and mean aortic pressure 
increased 16% from 88±10 mmHg to 102± 14 mmHg during EECP (P=0.0007), indicating 
significant. Intracoronary pressure was measured in an unobstructed epicardial coronary 
artery using the micromanometer-tipped 0.014-inch pressure wire. There was a 93% increase 
in intracoronary peak diastolic pressure (71±10 mmHg at baseline to 137±21 mmHg during 
EECP; P<0.0001;. (Michaels et al., 2002; Fig 3) 
Mean pressure increased by 16% from 88±9 mmHg at baseline to 102±16 mmHg during 
EECP (P=0.006). EECP decreased peak systolic pressure by 15% from 116±20 mmHg at 
baseline to 99±26 mmHg during EECP (P=0.002). Planimetry of the intracoronary pressure 
tracings showed a 28% increase in diastolic pressure (42±9 mmHg·sec at baseline;  
54±15 mmHg·sec during EECP; P=0.0003) and a 12% decrease in systolic pressure 
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Representative simultaneous hemodynamic tracings of central aortic pressure from the coronary 
catheter and intracoronary pressure from the PressureWire. In tracings of both phasic and mean 
pressure (bottom) obtained at the beginning of EECP (A), there is a gradual increase in peak diastolic 
(dashed arrows) and mean pressure with a decrease in peak systolic pressure (solid arrows) attributable 
to systolic unloading as the inflation pressure is increased in the EECP device. In another patient, 
diastolic augmentation is demonstrated during EECP at a cuff pressure of 300 mm Hg (B). The 
intracoronary coronary pressure was 5 mm Hg lower than central aortic pressure, attributable to diffuse 
coronary atherosclerosis. The paper speed is 25 mm/sec. ( With permission from Michaels AD,2002) 
Fig. 3. Hemodynamic tracings of central aortic pressure 
(33±6 mmHg·sec at baseline; 29±7 mmHg·sec during EECP; P=0.008). Intracoronary Doppler 
flow velocity was measured using a 0.014-inch FloWire (Fig 2). The average peak velocity 
increased 109% from 11±5 cm/s at baseline to 23 ±5 cm/s during EECP (P=0.001). The peak 
diastolic velocity increased 150% from 18±7 cm/s at baseline to 45±14 cm/s during EECP 
(P=0.0004). The diastolic-to-systolic velocity ratio increased 100% from 1.0±0.3 to 2.0±0.7 
during EECP (P=0.003). There was no significant change in peak systolic velocity. The 
CTFC, another measure of coronary flow velocity, significantly decreased 28% from 37±18 at 
baseline to 27±13 during EECP (P=0.001). This study provides solid evidence of the increase 
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in directly measured aortic and coronary diastolic pressure and flow velocity from EECP. 
There is a significant reduction in left ventricular afterload and left ventricle work secondary 
to systolic unloading.  
(Michaels et al., 2010) 
Acute hemodynamic effects of EECP can be summarized as: (Fig 4) 
1. Increased retrograde aortic blood flow; diastolic augmentation; 
2. Increased coronary blood flow ; increased perfusion pressure; 
3. Increased venous return; 
4. Increased cardiac output; 
5. Systolic unloading;  
6. Decreased left ventricular workload 
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Right upper corner: Showing the ECG tracing and finger pletysmogram. As soon as the device turned 
on (yellow line) diastolic augmentation starts. Right lower corner: showing the diastolic augmentation 
by echocardiography. EECP: Enhanced External Counterpulsation; a: aortic notch (With permission 
from Dr Soran and Katz 1998) 
 
 
Fig. 4. Acute hemodynamic effects of EECP Therapy 
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3. EECP therapy in CAD management 
Several nonrandomized and randomized trials have demonstrated a consistently positive 
clinical response among patients with CAD treated with EECP (Lawson et al. 1992, Arora et 
al. 1999). Benefits associated with EECP therapy include reduction in angina and nitrate use, 
increased exercise tolerance, favorable psychosocial effects, and enhanced quality of life as 
well as prolongation of the time to exercise-induced ST-segment depression and an 
accompanying resolution of myocardial perfusion defects. Numerous clinical trials in the 
past two decades have shown EECP therapy to be safe and effective for patients with CAD, 
with a clinical response rate averaging 70% to 80%, which is sustained up to 5 years. 
(Lawson et al. 2000; Masuda et al. 2001; Stys et al. 2002; Pettersson et al.2006; Braverman, 
DL. 2009).  
Most studies on EECP therapy cannot be double blind and lack good control groups because 
of technical limitations, drawbacks that have frequently raised questions regarding operator 
bias. However, the Multicenter Study of EECP (MUSTEECP), a randomized double-blinded 
placebo-controlled trial, did document a clinical benefit from EECP therapy in patients with 
chronic stable angina and positive exercise stress tests. In this study, 139 patients (mean age 
63 years, range 35 years to 81 years) with angina pectoris (typical Canadian Cardiovascular 
Society (CCS) classes I, II, and III angina) and documented coronary ischemia were equally 
randomized to hemodynamically inactive counterpulsation with EECP versus active 
counterpulsation. Patients in the active EECP therapy group showed a statistically 
significant increase in time to exercise-induced ST-segment depression when compared with 
sham and baseline, and reported a statistically significant decrease in the frequency of 
angina episodes when compared with sham and baseline. Exercise duration increased 
significantly in both groups; however, the increase was greater in the active EECP group. 
Moreover, a MUST-EECP sub study demonstrated a significant improvement in quality-of 
life parameters in patients assigned to active treatment, and this improvement was 
sustained during a 12-month follow-up (Arora et al. 2002).  
Tartaglia et al assessed the effect of EECP on exercise capacity and myocardial perfusion by 
comparing results of maximal exercise radionuclide testing pre- and post-EECP treatment. 
This prospective study included 25 patients with angina who had performed maximal 
symptom-limited exercise tolerance tests with Bruce protocol and radionuclide perfusion 
single-photon emission computed tomography (SPECT) study prior to and at completion of 
EECP treatment. After 35 h of EECP, 93% improved by at least one functional angina class. 
There is a significant improvement in their total treadmill times and a significant change in 
their peak double products, from 18,891 +/- 3,939 pre-EECP to 20,464 +/- 4,305 post-EECP 
exercise tolerance tests (p < 0.03). Pre EECP, 16 patients had ST-segment depression on their 
initial exercise tolerance tests. After EECP, 80% either no longer had ST depression or had a 
significant increase in their time to ST depression. The radionuclide perfusion scores also 
showed a significant reduction in ischemic segments. In this study, patients treated with 
EECP demonstrated a reduction in angina symptoms, improvement in exercise capacity,  
increase in time to ST-segment depression, and decrease in perfusion defects despite 
performing at a higher workload.  
In another study, investigators evaluated the effects of EECP therapy on dobutamine stress-
induced wall motion score among patients with angina pectoris. In this prospective study, 
43% of patients with severe chronic angina pectoris and had a positive dobutamine stress 
echocardiogram had normal or reduced dobutamine induced wall motion abnormalities 
after EECP therapy. (Bagger et al., 2004) 
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British investigators assessed the immediate and long-term effect of EECP in treatment of 
chronic stable refractory angina. Sixty-one patients were treated with EECP and 58 
completed a course of treatment. About 52% of patients suffered from CCS III and IV angina 
prior to EECP. Immediately post-EECP, angina improved by at least one CCS class in 86% 
and by two classes in 59%. At 1-year follow-up, sustained improvement in CCS was 
observed in 78% of the patients. The median weekly angina frequency and nitroglycerin use 
were significantly reduced immediately after EECP. In 48 patients, their mean exercise time 
improved significantly after EECP. Major-adverse events were rare. This study showed that 
for patients who fail to respond to conventional measures, a high proportion gain 
symptomatic benefit from EECP.  
In 2006, Swedish investigators assess the long-term outcome of EECP treatment at a 
Scandinavian centre, in relieving angina in patients with chronic refractory angina pectoris. 
55 patients were treated with EECP. CCS class, antianginal medication and adverse clinical 
events were collected prior to EECP, at the end of the treatment, and at six and 12 months 
after EECP treatment. Clinical signs and symptoms were recorded. EECP treatment 
significantly improved the CCS class in 79% of the patients with chronic angina pectoris. 
The reduction in CCS angina class was seen in patients with CCS class III and IV and 
persisted 12 months after EECP treatment. In accordance with the reduction in CCS classes 
there was a significant decrease in the weekly nitroglycerin usage. The results showed that 
EECP was a safe and effective treatment in CAD patients and the beneficial effects were 
sustained during a 12-months follow-up period. (Pettersson et al.,2006). 
Same year, Italian investigators tested efficacy of EECP on symptoms, myocardial ischaemia 
and cardiac performance in patients with intractable angina, refractory to surgical and 
medical treatment. Twenty-five patients (mean age 65 years) with persistent ischaemia 
notwithstanding optimal medical therapy or after interventional or surgical procedure, 
received EECP sessions for 35 h. Each patient underwent dobutamine stress 
echocardiography before and after treatment. Eighty-four percent of patients showed an 
increase in at least one functional angina class. Thirty-six percent of patients had a reduction 
in the area of inducible ischaemia at dobutamine stress echocardiography after treatment. 
They concluded that EECP therapy was effective in relieving symptoms in patients with 
refractory angina and may reduce inducible ischaemia at dobutamine stress 
echocardiography, especially in patients with reduced systolic function and compromised 
segmental kinesis. (Novo et al., 2006) 
Although randomized (including placebo-controlled) and nonrandomized studies have 
shown beneficial effects of EECP therapy, investigators saw the need to assess EECP’s 
effectiveness in real-world settings, leading them to develop the International EECP Patient 
Registry (IEPR) under the management of the University of Pittsburgh (Michaels et al. 2004, 
Soran et al., 2010). More than 5000 patients were enrolled in phase I and another 2500 
patients enrolled in phase II of the study, and more than 90 centers participated. Results 
from the IEPR and the EECP Clinical Consortium have demonstrated that the symptomatic 
benefit observed in controlled studies translates to the heterogeneous patient population 
seen in clinical practice. Moreover, follow-up data indicate that the clinical benefit may be 
maintained for up to 5 years in patients with a favorable initial clinical response (Lawson et 
al. 2000; Loh et al 2008) 
Soran et al., compared the efficacy, repeat EECP and 6-months major adverse cardiovascular 
events (MACE: Death/CABG/PCI/MI) free survival rates for patients treated with EECP 
for angina management in Europe (EU) with the United States (US); 4658 were  treated and 
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followed in the US and 262 in EU. EU were younger (p<0.001) with a higher proportion of 
men. Previous revascularization rate was higher in US (p<0.001). EU had less diabetes, 
hypertension, hyperlipidemia, multivessel disease, Class IV angina, and higher rates of 
nitroglycerin usage (p<0.001). After a mean treatment course of 34 hours, both groups 
showed a significant reduction in the severity of angina (78% vs 76%). Discontinuation of 
nitroglycerin usage was similar in both groups (50%). MACE during the treatment period 
was low in both groups (<3%).Compliance with the treatment course was better in EU 
(p<0.001). 
At 6-month follow up 66% of EU and 76% of US had maintained the improvement in angina 
class; survival rate was 99% in EU and 97% in US. MACE free survival rate was 92% in EU 
vs 90% in US. Repeat EECP rates at 6months follow up were significantly lower in EU (0.5% 
vs. 4%, p<0.01).Patients presenting for EECP treatment from EU and US populations 
showed very different baseline profiles. However, both cohorts achieved substantial 
reduction in angina with high event free survival rates at 6 months. (Soran et al., 2010) 
EECP was suggested as a safe treatment option for selected symptomatic PCI candidates 
with obstructive CAD. Baseline characteristics and 1-year outcome in 2 cohorts of PCI 
candidates presenting with stable symptoms: 323 patients treated with EECP in the IEPR, 
and 448 NHLBI Dynamic Registry patients treated with elective PCI, were compared. 
Compared with patients receiving PCI, IEPR patients had a higher prevalence of many risk 
factors including prior PCI prior coronary artery bypass grafting, prior myocardial 
infarction, history of congestive heart failure, and history of diabetes. Left ventricular 
ejection fraction was lower among IEPR patients (mean 50.3% vs 59.2%, p <0.001). At 1 year, 
survival was comparable in the 2 cohorts (98.7% IEPR vs 96.8% PCI, P = NS), as were rates 
of coronary artery bypass grafting during follow-up (4.5% IEPR vs 5.7% PCI, P = NS). At 1 
year, 43.7% of IEPR patients reported no anginal symptoms compared with 73.4% of 
Dynamic Registry patients (p <0.001). Rates of severe symptoms (CCS class III, IV, or 
unstable) at 1 year were 15.5% among IEPR patients and 9.5% in the Dynamic Registry (p = 
0.02). PCI candidates suitable for and treated with EECP had 1-year major event rates 
comparable to patients receiving elective PCI. These results suggested that EECP, as a 
noninvasive treatment, could be used as a first –line treatment with invasive 
revascularization reserved for EECP failures, or high –risk patients. (Holubkov et al., 2002). 
The results of this study warrant the initiation of a randomized controlled study to 
ascertain the efficacy of EECP combined with drug therapy as a first line treatment in 
selected patients with CAD. 
3.1 EECP therapy in CAD with left ventricular dysfunction 
When providing EECP therapy to patients with heart failure, the initial researchers were 
concerned primarily that the increased venous return resulting from EECP therapy might 
precipitate pulmonary edema in angina patients with severe left ventricular dysfunction 
(SLVD). 
Using outcomes data from 363 patients enrolled in the IEPR, Soran et al. (Soran et al. 2006, 
Soran et al. 2002) evaluated the safety and efficacy of EECP therapy in those with refractory 
angina pectoris and SLVD (ejection fraction [EF] < 35%). In this study patients’ average 
duration of clinical CAD was nearly 13 years; 84% had multivessel disease and 93% were 
not candidates for further revascularization due to the extent and severity of disease, LV 
dysfunction, co-morbid conditions, previous interventions, or risk/benefit ratio. Angina was 
severe (class III/IV) in 93% of patients. There was a high prevalence of cardiac risk factors 
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(i.e., 45% had DM, 85% had prior MI, ,78% had hyperlipidemia, 77% had a history of 
smoking and 82% had a family history of premature atherosclerotic cardiovascular disease). 
More than 50% reported quality of life as poor. On average, patients underwent an EECP 
treatment course of 32 hours, with 81% completing the course. Twelve percent discontinued 
due to a clinical event, and 7% stopped due to patient preference. Major adverse 
cardiovascular events that occurred over the course of EECP therapy were low (Death/ 
myocardial infarction [MI]/CABG/PCI<2%). After completion of treatment, there was a 
significant reduction in angina severity: 72% improved from severe angina to no or mild 
angina. Fifty-two percent of the patients stopped using nitroglycerin. There was also a 
significant increase in quality of life. At 2-year follow-up, angina reduction was maintained 
in 55% of patients, the survival rate was 83%, and event-free (death/MI/PCI/CABG)  
 
 
 
 
 
 
Event (CABG; PCI; MI) free survival rate at 2 years post EECP therapy in patients with coronary artery 
disease and SLVD (With permission from Dr. Soran; Soran et al 2006) 
CABG: Coronary Artery Bypass Grafting Surgery, MI: Myocardial Infarction, 
PCI: Percutaneaus Coronary Intervention, SLVD: Severe left ventricular dysfunction 
 
 
Fig. 5. Event Free Survival Rate at 2 years –Post EECP 
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survival was 70%. Forty-three percent had no cardiac hospitalization; 81% had no 
congestive heart failure event (Fig.5). They concluded that EECP therapy for angina is safe 
and effective in patients with SLVD who are not considered good candidates for 
revascularization by CABG or PCI. 
Estahbanaty et al., evaluated the effects of EECP on  systolic and diastolic cardiac function 
using echocardiography to measure left ventricular EF, end-systolic volume, end-diastolic 
volume, systolic wave (Sm), early diastolic wave (Ea), Vp, E/Ea, E/Vp, and diastolic 
function grade in 25 patients before and after 35 hours of EECP. EECP reduced end-systolic 
volume  and end-diastolic volume  and increased EF significantly in patients with baseline 
left ventricular EF ≤ 50%, baseline E/Ea ≥ 14 , baseline grade II or III diastolic dysfunction 
(decreased compliance) , baseline Ea <7 cm/s and baseline Sm <7 cm/s. These results 
demonstrated improved systolic and diastolic function in selected patients. (Estahbanaty et 
al., 2007) 
Lawson et al. evaluated CAD patients with preserved left ventricular function (PLV; EF > 
35%) and with SLVD (EF≤ 35%) who were treated with a 35-hour course of EECP. 
Bioimpedance measurements of cardiovascular function were obtained before the first and 
after the 35th hour of EECP therapy. Twenty-five patients were enrolled, 20 with PLV and 5 
with SLVD. Angina class improved similarly in both groups. The SLVD group, in contrast to 
the PLV group, had increased cardiac power (ie, mean arterial pressure × cardiac 
output/451), stroke volume, and cardiac index and decreased systemic vascular resistance 
with treatment. This study suggests that EECP may benefit patients experiencing CAD with 
SLVD directly by improving cardiac power and indirectly by decreasing systemic vascular 
resistance (Lawson et al. 2002).  
Patients with CAD and left ventricular dysfunction exert an enormous burden on health 
care resources, primarily because of the number of recurrent emergency department visits 
and hospitalizations. Improvements in symptoms and laboratory assessments in these 
patients may not correlate with a reduction in emergency room visits and hospitalizations. 
Soran et al. assessed the impact of EECP therapy on emergency department visits and 
hospitalization rates at 6-month follow up. In this prospective cohort study, clinical 
outcomes, number of all-cause emergency department visits, and hospitalizations within the 
6 months before EECP therapy were compared with those at 6-month follow-up. The mean 
number of emergency department visits per patient decreased from 0.9 ± 2.0 before EECP to 
0.2 ± 0.7 at 6 months (P < 0.001), and hospitalizations were reduced from 1.1 ± 1.7 to 0.3 ± 0.7 
(P < 0.001) (Soran et al. 2007). 
Scientific data indicates that EECP provides a safe and effective treatment option for 
patients with CAD and left ventricular dysfunction. 
4. Mechanism of action 
Upon diastole, cuffs inflate sequentially from the calves, raising diastolic aortic pressure 
proximally and increasing coronary perfusion pressure. Compression of the vascular beds of 
the legs also increases venous return. Instantaneous decompression of all cuffs at the onset 
of systole significantly unloads the left ventricle, thereby lowering vascular impedance and 
decreasing ventricular workload. This latter effect, when coupled with augmented venous 
return, raises cardiac output. In summary, EECP therapy increases venous return, raises 
cardiac preload, increases cardiac output, and decreases systemic vascular resistance 
(Michaels et al. 2002). 
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Mechanism of action of EECP therapy is not through one pathway, but several pathways 
affecting each other. (Fig.6) 
 
Acute Effects during EECP treatment
as a Circulatory Assisted Device
Workload of the heart
Coronary blood flow
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Quality of Life
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Ejection Fraction
Functional Class
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Possible mechanisms responsible for the clinical benefit associated with EECP therapy. Acute 
hemodynamic and neurohormonal changes, prolonged stimulus to increase  sheer stress which 
promotes endothelial function improvement  is thought to promote myocardial collateralization via 
opening of latent conduits,  arteriogenesis, and angiogenesis. 
HGF:  hepatocyte growth factor, bFGF: basic Fibroblast Growth Factor, VEGF: Vascular endothelial 
growth factor, TNF: Tumor necrosis factor-alpha, MCP-1: Monocyte chemotactic protein-1, 
cGMP: Cyclic guanosine monophosphate 
Fig. 6. Mechanism of EECP Therapy 
4.1 Collateral development 
One of the mechanisms of action is through collateral development. Mode-of-action studies 
have shown that EECP therapy increases angiogenesis factors such as human growth, basic 
fibroblast growth, and vascular endothelial growth factors. Enhanced diastolic flow 
increases shear stress, increased shear stress activates the release of growth factors, and 
augmentation of growth factor release activates angiogenesis.(Soran et al., 1999) 
To clarify the mechanism of action of EECP therapy, Masuda et al used (13) N-ammonia 
positron emission tomography to evaluate myocardial perfusion. Eleven patients (mean age: 
61 years) with angina pectoris underwent EECP therapy for 35 1 h sessions. Treadmill 
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exercise test and (13) N-ammonia positron emission tomography, both at rest and with 
dipyridamole, before and after EECP therapy were performed. Neurohumoral factors and 
nitric oxide were also evaluated. Myocardial perfusion increased significantly at rest after 
therapy. In ischemic regions, particularly the anterior region, myocardial perfusion at rest 
and with dipyridamole and coronary flow reserve improved significantly after therapy. 
Exercise time was prolonged and the time to 1-mm ST depression improved markedly. After 
therapy, nitric oxide levels increased significantly and neurohumoral factors decreased. 
These results suggest that one of the mechanisms of the therapy is development and 
recruitment of collateral vessels. (Masuda et al., 2001). 
To test the hypothesis that EECP augments collateral function Gloekler et al randomized 
patients with chronic stable angina to EECP therapy or sham treatment. Before and after 30 
h of randomly allocated EECP or sham EECP, the invasive collateral flow index (CFI) was 
obtained in 34 vessels. CFI was determined by the ratio of mean distal coronary occlusive 
pressure to mean aortic pressure with central venous pressure subtracted from both. 
Additionally, coronary collateral conductance (occlusive myocardial blood flow per aorto-
coronary pressure drop) was determined by myocardial contrast echocardiography and 
brachial artery flow-mediated dilatation was obtained. CFI significantly improved in the 
EECP group but not in the sham treatment. EECP appeared to be effective in promoting 
coronary collateral growth. The extent of collateral function improvement was related to the 
amount of improvement in the systemic endothelial function (Gloekler et al. 2010). 
4.2 Endothelial function improvement 
Another mechanism of action of EECP therapy is through endothelial changes. EECP therapy 
improves endothelial function and enhances vascular reactivity. Akhtar et al examined the 
effects of EECP on plasma nitric oxide and endothelin-1 (ET-1) levels. Plasma nitrate and 
nitrite (NOx) and ET-1 levels were measured serially in 13 patients with coronary artery 
disease who received 1-hour daily treatments of EECP over 6 weeks. During the course of 
EECP therapy, plasma NOx progressively increased and plasma ET-1 progressively decreased. 
After 36 hours of EECP, there was a 62 % increase in plasma NOx compared with baseline ( p 
<0.0001) and a 36% decrease in plasma ET-1 ( p <0.0001). At 3 months after completion of 
EECP, NOx remained 12% above baseline (p = 0.002), and ET-1 remained 11% below baseline 
(p = 0.0068). This data provides neurohormonal evidence to support the hypothesis that EECP 
improves endothelial function.(Akhtar  Am J Cardiol 2006) 
Braith et al investigated the effects of EECP on peripheral artery flow-mediated dilation in a 
randomized placebo-controlled study. Symptomatic patients with CAD were randomized 
(2:1 ratio) to thirty-five 1-hour sessions of either EECP or sham EECP . Flow-mediated 
dilation of the brachial and femoral arteries was performed with the use of ultrasound. 
Plasma levels of nitrate and nitrite, 6-ketoprostaglandin, F1α, endothelin-1, asymmetrical 
dimethylarginine, tumor necrosis factor-α, monocyte chemoattractant protein-1, soluble 
vascular cell adhesion molecule, high-sensitivity C-reactive protein, and 8-isoprostane were 
measured. EECP significantly increased brachial and femoral artery flow-mediated dilation, 
the nitric oxide turnover/production markers nitrate and nitrite and 6-keto-prostaglandin 
F1α, whereas it decreased endothelin-1 and the nitric oxide synthase inhibitor asymmetrical 
dimethylarginine in treatment versus sham groups, respectively. EECP significantly 
decreased the proinflammatory cytokines tumor necrosis factor-α, monocyte 
chemoattractant protein-1 , soluble vascular cell adhesion molecule-1, high-sensitivity C-
reactive protein, and the lipid peroxidation marker 8-isoprostane in treatment versus sham 
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groups, respectively. EECP also significantly reduced angina classification in treatment 
versus sham groups, respectively. Findings from this study provide novel mechanistic 
evidence that EECP has a beneficial effect on peripheral artery flow-mediated dilation and 
endothelial-derived vasoactive agents in patients with symptomatic CAD (Braith et al. 2010).  
It is known that cGMP regulates vascular smooth muscle tone that may improve arterial 
function. French investigators assessed the effect of a single session of EECP on plasma and 
platelet Cyclic GMP (cGMP) in asymptomatic subjects with cardiovascular risk factors and 
in patients with CAD. Fifty-five subjects were randomized into two groups to receive either 
sham (control) or active EECP during 1 h. Plasma and platelet cGMP were measured 
immediately before and after EECP by radioimmunoassay. One hour of EECP increased 
cGMP plasma concentration by 52% ± 66% (SD) (P< .001) and platelet content by 19%± 28% 
(P < .01). The increase in plasma cGMP was particularly marked in CAD patients receiving 
active EECP (P<.01), mainly in those with low LDL cholesterol. Platelets, inhibition of nitric 
oxide synthesis by NG-monomethyl-L-arginine (L-NMMA) reduced cGMP by 23% ± 31% (P 
_ .001), whereas presence of superoxide dismutase and inhibition of phosphodiesterase-5 
increased cGMP by 46% ± 49% and 70% ± 77%, respectively (P <.001). In all of the cases 
EECP increased additional platelet cGMP content, which suggests nitric oxide synthase 
activation. These acute results showed that very early treatment increases the cGMP 
production that may participate in the mechanism by which EECP exerts its clinical benefit. 
Analysis of the modulation of platelet cGMP content suggests that EECP activated the nitric 
oxide-dependent pathways. (Levenson et al., 2006) 
4.3 Neurohormanal changes 
As with athletic training, the vascular effects of EECP therapy may be mediated through 
changes in the neurohormonal milieu. Wu et al. showed that EECP therapy has a sustained, 
dose-related effect in stimulating endothelial cell production of the vasodilator nitric oxide 
(NO) and in decreasing production of the vasoconstrictor endothelin. (Wu et al. 1999). In 
another study, Qian et al. showed that the NO level increased linearly in proportion to the 
hours of EECP treatment.(Qian X et al. 1999). Urano et al. further showed that plasma brain 
natriuretic peptide levels decreased after EECP therapy and were positively correlated with 
left ventricular end diastolic pressure and negatively correlated with peak filling rate. They 
concluded that EECP therapy reduces exercise-induced myocardial ischemia in association 
with improved left ventricular diastolic filling in patients with CAD. (Urano et al. 2001) 
Another possible mechanism explaining EECP’s mode of action is that it may affect changes 
in ventricular function independent of changes in cardiac load. Gorcsan et al. evaluated the 
effects of EECP therapy on left ventricular function in New York Heart Association class II 
or III heart failure patients with an EF less than 40%. Their results showed that EECP 
treatment was associated with improvements in preload adjusted maximal power, a 
relatively load-independent measure of left ventricular performance and EF, along with a 
decrease in heart rate in these heart failure patients. (Gorcsan et al. 2000) 
4.4 Anti-inflammatory effect 
A recently published randomized controlled study examining the effect of EECP therapy on 
inflammatory and adhesion molecules in patients with CAD indicated that EECP therapy 
has an anti-inflammatory effect in patients with angina pectoris. Patients were randomly 
assigned to receive active EECP or sham treatment. Plasma tumor necrosis factor- α, 
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monocyte chemoattractant protein-1, and soluble vascular cell adhesion molecule-1 were 
measured before and after a full course of 35 1-hour sessions of EECP or sham treatment. 
Patients in the EECP group demonstrated reductions in tumor necrosis factor-α and 
monocyte chemoattractant protein-1 after treatment, whereas those in the sham therapy 
group showed no changes. EECP therapy decreased circulating levels of proinflamatory 
biomarkers in patients with symptomatic CAD (Casey et al. 2008). 
5. Patient selection 
5.1 Indications 
FDA Labeled indications for the use of EECP include treatment of patients with: 
- Stable or unstable angina pectoris 
- Congestive heart failure 
- Acute MI 
- Cardiogenic shock 
5.2 Which group of patients may benefit from EECP therapy? 
Patients with angina or angina equivalent symptoms such as shortness of breath and/or 
fatigue who: 
- have coronary anatomy unsuitable for surgical or catheter-based revascularization 
- inadequately respond to optimum medical therapy 
- underwent incomplete invasive revascularization 
- are considered inoperable or at high risk of operative/interventional complications 
- have comorbid conditions that increase the risk of revascularization procedures, such as 
diabetes, heart failure, pulmonary disease, and renal dysfunction 
- are unwilling to undergo additional invasive revascularization procedures 
- have stable (NYHA class II or III) heart failure; patients with any evidence of 
decompensation should not be treated until they are stable with the use of medical 
therapy 
- have ischemic or idiopathic cardiomyopathy 
- have cardiac syndrome X or microvascular ingina 
- have LVD (EF < 35%) 
5.3 Contraindications and side effects 
It is important to point out that EECP therapy is not for everyone. This noninvasive 
outpatient procedure can be somewhat uncomfortable for patients because of the 
highpressure sequential compression of the cuffs. It is not recommended for certain types of 
valvular heart disease (especially aortic insufficiency), or for those with recent cardiac 
catheterization, an irregular heart rhythm, severe hypertension, significant blockages in the 
leg arteries, or a history of deep venous thrombosis. For anyone else, however, the 
procedure seems to be quite safe. 
5.4 Contraindications 
- Moderate to severe aortic insufficiency (regurgitation would prevent diastolic 
augmentation) 
- Arrhythmias that may interfere with EECP system triggering (uncontrolled atrial 
fibrillation or fl utter or very frequent premature ventricular contractions) 
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- Coagulopathy with an INR of prothrombin time greater than 2.5 
- Severe hypertension: greater than 180/110 mm Hg (the augmented diastolic pressure 
may exceed safe limits) 
- Cardiac catheterization or arterial puncture (risk of bleeding at femoral puncture site) 
within the past 2 weeks 
- Decompensated heart failure 
- Severe peripheral arterial disease (reduced vascular volume and muscle mass may 
prevent active counterpulsation) 
- Aortic aneurysm (≥ 5 mm) or dissection (diastolic pressure augmentation may be 
deleterious) 
- Pregnancy or being of childbearing age (effects of EECP therapy on the fetus have not 
been studied) 
- Venous disease (phlebitis, varicose veins, stasis ulcers, prior or current deep vein 
thrombosis or pulmonary embolism) 
- Severe chronic obstructive pulmonary disease (no safety data in pulmonary 
hypertension) 
5.5 Side effects  
- Skin abrasion or ecchymoses 
- Bruises (especially in patients using warfarin in whom the international normalized 
ratio [INR] is not adjusted) 
- Paresthesias 
- Leg or waist pain 
- Worsening of heart failure in patients with severe arrhythmias 
6. Future research 
Throughout the world, EECP therapy has been studied for various potential uses other than 
heart disease ((Offergeld et al 2000; Rajaram et al 2006; Hilz et al 2004; Myhre et al 2004).  
*Cardiac Syndrome X: its role in improving endothelial function might be beneficial in the 
treatment of patients with Cardiac Syndrome X, which is marked by severe chest pain 
caused by myocardial dysfunction, often without detectable atherosclerosis. Investigators 
have reported successful treatment of Cardiac Syndrome X with severely symptomatic 
coronary endothelial dysfunction in the absence of obstructive CAD with standard 35-h 
course of EECP therapy (Bonetti et al 2004).  
*Acute M/Cardiogenic Shock: Based on its acute haemodynamic effects, comparable to 
those of IABP, EECP can be proposed as a potential treatment for coronary syndromes in 
acute setting, as an inpatient therapy for patients with IABP contraindications. Recently 
developed mobile EECP Therapy system, enables its use in the catheter laboratory and 
operation room settings. 
*Erectile dysfunction: Studies looking at EECP therapy and erectile dysfunction have 
shown a 200% increase in penile artery flow and reported improvement in erectile function 
[Froschermaier et al 1998; Lawson et al 2007; El-Sakka AI et al 2007 
*Hepatorenal syndrome: Werner et al. assessed the potential role of EECP therapy in 
diuresis and increased urinary fl ow in patients with endstage liver disease awaiting a 
transplant. They found that EECP therapyincreased mean arterial pressure as well as 
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urinary production (urinary flow rate) in patients with end-stage cirrhosis and hepatorenal 
syndrome. (Werner et al 2005. )Studies involving larger sample sizes are necessary to 
confirm the effectiveness of EECP therapy in erectile dysfunction and hepatorenal 
syndrome. 
* Ischemic stroke: Investigators sought to determine effect of EECP on middle cerebral 
artery blood flow augmentation in normal controls as a first step to support future clinical 
trials in acute stroke. (Alexandrow et al.,2008) 
* Primary /Secondary Prevention: New studies are under way to explore the role of EECP 
therapy in primary and secondary prevention of coronary artery disease and its potential 
use in failing fontan operation. 
7. Conclusion 
Scientific data indicates that EECP provides a safe and effective treatment option for 
patients with CAD. Its different mode of action complements the invasive revascularization 
treatment. Currently, The American College of Cardiology/ The American Heart 
Association recommends EECP Therapy as a Class IIb (Level of Evidence: B) intervention 
for treatment of CAD. Due to the volume and quality of scientific data now available and 
per the descriptions of the rating and evidence levels as defined by American College of 
Cardiology and American Heart Association guidelines it is believed that EECP therapy has 
earned a Class IIa treatment recommendation with level of evidence A. 
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